clinical trial · NCT05764590
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
Alebund Pharmaceuticals·phase2·completed·n = 55
Chronic Kidney DiseasesHyperphosphatemiaAP-306Sevelamer Carbonate
brief summary
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: * How much effect AP-306 has assessed by blood phosphorus lowering; * How safe and tolerable AP-306 is. Participants will receive either following treatments: * AP-306, and * Sevelamer carbonate.
started
Feb 20, 2023
primary completion
Aug 25, 2023
completion
Sep 14, 2023
last updated
Jan 10, 2024
official title
A Phase 2, Randomized, Open-Label, Active-Controlled, Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol